Exact Mass: 261.1953
Exact Mass Matches: 261.1953
Found 249 metabolites which its exact mass value is equals to given mass value 261.1953,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Phenindamine
Phenindamine is an antihistamine. Phenindamine blocks the effects of the naturally occurring chemical histamine in your body. Antihistamines such as phenindamine appear to compete with histamine for histamine H1- receptor sites on effector cells. The antihistamines antagonize those pharmacological effects of histamine which are mediated through activation of H1- receptor sites and thereby reduce the intensity of allergic reactions and tissue injury response involving histamine release. It is used to treat sneezing, runny nose, itching, watery eyes, hives, rashes, itching, and other symptoms of allergies and the common cold. Symptoms of a phenindamine overdose include extreme sleepiness, confusion, weakness, ringing in the ears, blurred vision, large pupils, dry mouth, flushing, fever, shaking, insomnia, hallucinations, and possibly seizures. R - Respiratory system > R06 - Antihistamines for systemic use > R06A - Antihistamines for systemic use D018377 - Neurotransmitter Agents > D018494 - Histamine Agents > D006633 - Histamine Antagonists C308 - Immunotherapeutic Agent > C29578 - Histamine-1 Receptor Antagonist
Acrifoline
A quinolizidine alkaloid that is lycopodine having a C=C double bond at the 11-position, a keto substituent at the 8-position and the keto group at position 5 replaced by a beta-hydroxy group.
Bufuralol
C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C72900 - Adrenergic Antagonist D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D018674 - Adrenergic Antagonists Bufuralol (Ro 3-4787) is a potent non-selective, orally active β-adrenoreceptor antagonist with partial agonist activity. Bufuralol hydrochloride is a CYP2D6 probe substrate[1][2][3][4].
Hexylcaine
Hexylcaine hydrochloride, also called cyclaine (Merck) or osmocaine, is a short-acting local anesthetic. It acts by inhibiting sodium channel conduction. Overdose can lead to headache, tinnitus, numbness and tingling around the mouth and tongue, convulsions, inability to breathe, and decreased heart function. C78272 - Agent Affecting Nervous System > C245 - Anesthetic Agent
desmethylcyclobenzaprine
desmethylcyclobenzaprine is a metabolite of cyclobenzaprine. Cyclobenzaprine, brand name Flexeril, is a muscle relaxant medication used to relieve skeletal muscle spasms and associated pain in acute musculoskeletal conditions. It is the most well-studied drug for this application, and it also has been used off-label for fibromyalgia treatment. A new bedtime formulation of cyclobenzaprine is under development for the management of fibromyalgia syndrome. (Wikipedia)
Hydroxyl frovatriptan
Hydroxyl frovatriptan is a metabolite of frovatriptan. Frovatriptan (trade name Frova) is a triptan drug developed by Vernalis for the treatment of migraine headaches and for short term prevention of menstrual migraine. The product is licensed to Endo Pharmaceuticals in North America and Menarini in Europe. (Wikipedia)
Beta-hydroxyisovaleroylcarnitine
3-Hydroxyisovalerylcarnitine is structual derivative of 3-hydroxyisovaleric acid and carnitine. Due to its increased concentration in blood, 3-hydroxyisovalerylcarnitine (C5OH-I) is an important indicator for the diagnosis of organic acidemias in newborns (PMID: 18088573). Analysis of acylcarnitines by tandem mass spectrometry (MS/MS) has recently been used to screen newborns for organic acidemias and fatty acid oxidation defects (PMID: 7494654, 9216448, 11427446, 12127323, 14578311). These diseases cause the accumulation of acyl-CoA, which is esterified to acylcarnitine by carnitine acyltransferase. Acylcarnitine is then eliminated in the urine, thus acylcarnitine concentration serves as an excellent indicator for these diseases (PMID: 6361812). 3-Hydroxyisovalerylcarnitine (C5OH-I) is an indicator for diagnoses of multiple carboxylase deficiency (MCD), 3-methylcrotonyl-CoA carboxylase deficiency and 3-hydroxy-3-methylglutaryl-CoA lyase deficiency (PMID: 18088573), which are inborn errors of metabolism.
hydroxyisovaleroyl carnitine
hydroxyisovaleroyl carnitine is classified as a member of the Acyl carnitines. Acyl carnitines are organic compounds containing a fatty acid with the carboxylic acid attached to carnitine through an ester bond. hydroxyisovaleroyl carnitine is considered to be practically insoluble (in water) and acidic. hydroxyisovaleroyl carnitine is a fatty ester lipid molecule
2-Hydroxyisovalerylcarnitine
2-Hydroxyisovalerylcarnitine belongs to the class of organic compounds known as acylcarnitines. These are organic compounds containing a fatty acid with the carboxylic acid attached to carnitine through an ester bond. 2-Hydroxyisovalerylcarnitine is an extremely weak basic (i. e. Human blood levels of 2-hydroxyisovalerylcarnitine were reported to be influenced by genetic variants in the gene HLCS which codes for the enzyme holocarboxylase synthetase (PMID: 26401656). Holocarboxylase synthetase deficiency (OMIM: 253270), also called HLCS deficiency, is a rare inborn error of metabolism (IEM) and autosomal recessive disorder caused by a defective holocarboxylase synthetase. Individuals with HLCS deficiency are unable to utilize biotin effectively.
(2S,3R)-3-Hydroxy-2-methylbutanoylcarnitine
(2S,3R)-3-Hydroxy-2-methylbutanoylcarnitine is an acylcarnitine. More specifically, it is an (2S,3R)-3-hydroxy-2-methylbutanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (2S,3R)-3-Hydroxy-2-methylbutanoylcarnitine is therefore classified as a short chain AC. As a short-chain acylcarnitine (2S,3R)-3-Hydroxy-2-methylbutanoylcarnitine is a member of the most abundant group of carnitines in the body, comprising more than 50\\% of all acylcarnitines quantified in tissues and biofluids (PMID: 31920980). Some short-chain carnitines have been studied as supplements or treatments for a number of diseases, including neurological disorders and inborn errors of metabolism. Carnitine acetyltransferase (CrAT, EC:2.3.1.7) is responsible for the synthesis of all short-chain and short branched-chain acylcarnitines (PMID: 23485643). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
3-Hydroxyvalerylcarnitine
3-Hydroxyvalerylcarnitine is an acylcarnitine. More specifically, it is an 3-hydroxypentanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 3-Hydroxyvalerylcarnitine is therefore classified as a short chain AC. As a short-chain acylcarnitine 3-Hydroxyvalerylcarnitine is a member of the most abundant group of carnitines in the body, comprising more than 50\\% of all acylcarnitines quantified in tissues and biofluids (PMID: 31920980). Some short-chain carnitines have been studied as supplements or treatments for a number of diseases, including neurological disorders and inborn errors of metabolism. In particular 3-Hydroxyvalerylcarnitine is elevated in the blood or plasma of individuals with 3-hydroxy-3-methylglutaryl-coenzyme A lyase deficiency (PMID: 28583327) and holocarboxylase synthetase deficiency (PMID: 27114915). It is also decreased in the blood or plasma of individuals with psoriasis (PMID: 33391503). Carnitine acetyltransferase (CrAT, EC:2.3.1.7) is responsible for the synthesis of all short-chain and short branched-chain acylcarnitines (PMID: 23485643). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
5-Hydroxypentanoylcarnitine
5-hydroxypentanoylcarnitine is an acylcarnitine. More specifically, it is an 5-hydroxypentanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 5-hydroxypentanoylcarnitine is therefore classified as a short chain AC. As a short-chain acylcarnitine 5-hydroxypentanoylcarnitine is a member of the most abundant group of carnitines in the body, comprising more than 50\\% of all acylcarnitines quantified in tissues and biofluids (PMID: 31920980). Some short-chain carnitines have been studied as supplements or treatments for a number of diseases, including neurological disorders and inborn errors of metabolism. In particular 5-hydroxypentanoylcarnitine is elevated in the blood or plasma of individuals with 3-hydroxy-3-methylglutaryl-coenzyme A lyase deficiency (PMID: 28583327) and holocarboxylase synthetase deficiency (PMID: 27114915). It is also decreased in the blood or plasma of individuals with psoriasis (PMID: 33391503). Carnitine acetyltransferase (CrAT, EC:2.3.1.7) is responsible for the synthesis of all short-chain and short branched-chain acylcarnitines (PMID: 23485643). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
Pinacidil pyridine N-oxide
Setiptiline
C78272 - Agent Affecting Nervous System > C265 - Antidepressant Agent > C94727 - Tricyclic Antidepressant Setiptiline (Org-8282) is a serotonin receptor antagonist. Setiptiline is a tetracyclic antidepressant (TeCA) which acts as a noradrenergic and specific serotonergic antidepressant (NaSSA). Setiptiline acts as a norepinephrine reuptake inhibitor, α2-adrenergic receptor antagonist, and serotonin receptor antagonist, likely at the 5-HT2A, 5-HT2C, and/or 5-HT3 subtypes, as well as an H1 receptor inverse agonist/antihistamine.
Zilpaterol
Axisothiocyanate 4
Zilpaterol
C78273 - Agent Affecting Respiratory System > C29712 - Anti-asthmatic Agent > C319 - Bronchodilator
Prodine
D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants > D009294 - Narcotics D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents C78272 - Agent Affecting Nervous System > C67413 - Opioid Receptor Agonist D002491 - Central Nervous System Agents > D000700 - Analgesics
2-Amino-1,3,4-tetradecanetriol
A tetrol that is 2-aminotetradecane with the theree hydroxy substituents located at position 1, 3, and 4.
dodeca-2,4,8,10-tetraenoic acid 2-methylbutylamide
3,10-Dioxo-12-methyl-decahydro-1H-8,10b-propano-benzo(ij)chinolin|3,10-Dioxo-12-methyl-decahydro-1H-8,10b-propano-benzochinolin|3,10-Dioxo-12-methyldecahydro-1H-8,10b-propano-benzochinolizin
(E,Z)-N-[2-(1H-Imidazol-4-yl)ethyl]-2,4-decadienamide
8-Deoxy-13-dehydroserratinin|8-deoxy-13-dehydroserratinine
(?)-4-(4-methoxyphenyl)-1-piperidin-2-ylbutan-2-one|1-(2-piperidyl)-4-(p-methoxyphenyl)-2-butanone|1-(2-piperidyl)-4-(p-methoxyphenyl)-butanone-2
(5aR,7S,8R)-8-butyl-2,3,4,5,5a,6,7,8-octahydro-2-imino-7-methylcyclopenta[de]quinazolin-8-ol|1,8a:8b,3a-didehydro-8alpha-hydroxyptilocaulin|8alpha-hydroxymirabilin B
(2E,4E,8E,10E)-N-(2-methylpropyl)-12-oxododeca-2,4,8,10-tetraenemide|Lanyuamide V
1-(4-dimethylamino-butyryl)-2-pyridin-3-yl-pyrrolidine|N-(4-Dimethylaminobutanoyl)nornicotin
(2S,6R,7S,8S)-2-allyl-7-((E)-buta-1,3-dien-1-yl)-1-azaspiro[5.5]undecan-8-ol
3-Hydroxyisovalerylcarnitine
3-hydroxyisovalerylcarnitine is an O-acylcarnitine having 3-hydroxyisovaleryl as the acyl substituent. It has a role as a human metabolite. It is functionally related to a 3-hydroxyisovaleric acid. 3-Hydroxyisovalerylcarnitine is a specific amino acid derivative that belongs to the class of compounds known as carnitines. This molecule plays a crucial role in the transport of fatty acids into the mitochondria for oxidation, a key process in energy production. The name "3-Hydroxyisovalerylcarnitine" reflects its chemical structure: it consists of a carnitine moiety attached to a 3-hydroxyisovaleryl group. The term "3-hydroxyisovaleryl" refers to a side chain derived from a pentanoic acid (a five-carbon acid) that contains a hydroxyl group (-OH) bonded to the third carbon atom in the chain. This hydroxyl group is critical for the compound's function and is a distinguishing feature of this particular carnitine derivative. 3-Hydroxyisovalerylcarnitine involved in fatty acid metabolism, characterized by its unique hydroxyisovaleryl substituent attached to the carnitine backbone.
4-[4-(Piperidinomethyl)pyridyl-2-oxy]-cis-2-butenamine
1-benzyl-4-(dimethylamino)piperidine-4-carboxamide
(4-(Cyclohexyl(methyl)carbamoyl)phenyl)boronic acid
Piperidine,2-[(2S,4S)-2-ethyl-2-phenyl-1,3-dioxolan-4-yl]-, (2S)-
3-(N-Methylaminocarbonyl)phenylboronic acid, pinacol ester
tert-Butyl (5-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)methylcarbamate
6-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)-3,4-dihydro-2H-pyrano[2,3-b]pyridine
2-(3-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)acetamide
N,N-DIMETHYL-1-(3-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)PHENYL)METHANAMINE
(S)-2-amino-N-((S)-3-Methyl-2-oxo-2,3,4,5-tetrahydro-1H-benzo[d]azepin-1-yl)propanamide
2-(4-Methoxybenzyl)-1,3,3-triMethylpiperidin-4-one
7,7-dimethyl-3-pentyl-6,8-dihydro-1H-quinoline-2,5-dione
4-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)ACETANILIDE
(s)-methyl 4-(boc-(methyl)amino)-5-hydroxypentanoate
[8-(3-Methylphenyl)-1,4-dioxaspiro[4.5]dec-8-yl]Methylamine
alpha,alpha,alpha-trimethyl-1,3,5-triazine-1,3,5(2H,4H,6H)-triethanol
Ethyl 1-benzyl-4,4-dimethylpyrrolidine-3-carboxylate
4-((n,n-dimethylamino)methyl)phenylboronic acid pinacol ester hydrochloride
Amixetrine
C78272 - Agent Affecting Nervous System > C241 - Analgesic Agent > C2198 - Nonnarcotic Analgesic
N-BOC-(2R,3S)-2-HYDROXY-3-AMINO-5-METHYLHEXANOIC ACID
N-CYCLOPROPYL-5-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)PYRIMIDIN-2-AMINE
Boc-(2S,3R)-3-amino-2-hydroxy-5-methylhexanoic acid
(2S,3S)-3-((TERT-BUTOXYCARBONYL)AMINO)-2-HYDROXY-5-METHYLHEXANOIC ACID
1-Piperidinecarboxylic acid, 4-phenyl-, 1,1-dimethylethyl ester
7-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)-3,4-dihydro-2H-benzo[b][1,4]oxazine
DIMETHYL-[2-(4,4,5,5-TETRAMETHYL-[1,3,2]DIOXABOROLAN-2-YL)-BENZYL]-AMINE
N-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide
4-Piperidinecarboxamide,4-(ethylamino)-1-(phenylmethyl)-
(R)-N-(3-((2-AMINOETHYL)AMINO)-3-OXOPROPYL)-2,4-DIHYDROXY-3,3-DIMETHYLBUTANAMIDE
N-[2-(Isopropylamino)ethyl]-1,2,3,4-tetrahydro-3-isoquinolinecarboxamide
1-Piperidinecarboxylic acid, 3-hydroxy-4,4-dimethoxy-, 1,1-dimethylethyl ester
(3-(CYCLOHEXYL(METHYL)CARBAMOYL)PHENYL)BORONIC ACID
ethyl (1S,2S)-2-[(1S)-phenylethyl]aminocyclopentane-1-carboxylate
N-Isopropyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline
propan-2-yl 1-methyl-4-phenylpiperidine-4-carboxylate
1-Cyclopropyl-6-oxo-1,6-dihydropyridine-3-boronic acid pinacol ester
3-Methyl-1-(tricyclo[3.3.1.1(3,7)]dec-1-ylcarbonyl)piperidine
4-(3,4-diethoxyphenyl)-3-methyl-1H-pyrazol-5-amine
4-[1-(4,5-DIHYDRO-4,4-DIMETHYL-2-OXAZOLYL)-1-METHYLETHYL]-BENZENEETHANOL
2-(Ethylaminomethyl)phenylboronic acid,pinacol ester
1-METHYL-5-AMINO-1H-BENZIMIDAZOLE-2-BUTANOIC ACID ETHYLESTER
boc-(2r,3r)-3-amino-2-hydroxy-5-methylhexanoic acid
N-[3-[(2-Cyanoethyl)ethylamino]-4-methoxyphenyl]acetamide
ethoheptazine
C78272 - Agent Affecting Nervous System > C67413 - Opioid Receptor Agonist
9-Hydroxy-10-(propan-2-ylamino)-1,3-diazatricyclo[6.4.1.0^{4,13}]trideca-4(13),5,7-trien-2-one
(2S)-2-amino-N-[(2S)-1-amino-4-methylsulfanyl-1-oxobutan-2-yl]-4-methylpentanamide
dl-alpha-Prodine
D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants > D009294 - Narcotics D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents D002491 - Central Nervous System Agents > D000700 - Analgesics
Setiptiline
C78272 - Agent Affecting Nervous System > C265 - Antidepressant Agent > C94727 - Tricyclic Antidepressant Setiptiline (Org-8282) is a serotonin receptor antagonist. Setiptiline is a tetracyclic antidepressant (TeCA) which acts as a noradrenergic and specific serotonergic antidepressant (NaSSA). Setiptiline acts as a norepinephrine reuptake inhibitor, α2-adrenergic receptor antagonist, and serotonin receptor antagonist, likely at the 5-HT2A, 5-HT2C, and/or 5-HT3 subtypes, as well as an H1 receptor inverse agonist/antihistamine.
(3S)-3-[(3-hydroxypentanoyl)oxy]-4-(trimethylazaniumyl)butanoate
(R)-3-((3-Hydroxy-3-methylbutanoyl)oxy)-4-(trimethylammonio)butanoate
2-Amino-5,6-dimethyl-benzimidazole-1-pentanoic acid
2-[(Dimethylamino)methyl]-4-methyl-6-(1-methylcyclohexyl)phenol
3-Hydroxy-3-[hydroxy-(trimethylazaniumyl)methyl]-6-methyl-4-oxoheptanoate
(1E)-1-[(2-methylphenyl)hydrazinylidene]-1-morpholin-4-ylpropan-2-one
1-Benzyl-3-trimethylsilanyloxy-1,2,3,6-tetrahydropyridine
Phenindamine
R - Respiratory system > R06 - Antihistamines for systemic use > R06A - Antihistamines for systemic use D018377 - Neurotransmitter Agents > D018494 - Histamine Agents > D006633 - Histamine Antagonists C308 - Immunotherapeutic Agent > C29578 - Histamine-1 Receptor Antagonist
Bufuralol
C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C72900 - Adrenergic Antagonist D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D018674 - Adrenergic Antagonists Bufuralol (Ro 3-4787) is a potent non-selective, orally active β-adrenoreceptor antagonist with partial agonist activity. Bufuralol hydrochloride is a CYP2D6 probe substrate[1][2][3][4].
Hydroxyisovaleroylcarnitine
An O-acylcarnitine having 3-hydroxyisovaleryl as the acyl substituent.
O-(3-hydroxyvaleryl)-L-carnitine
An O-acyl-L-carnitine in which the acyl group is specified as 3-hydroxyvaleryl.
O-(hydroxyvaleryl)carnitine
An O-acylcarnitine having hydroxyvaleryl as the acyl substituent in which the position of the hydroxy group is unspecified.
O-hydroxyvaleroyl-L-carnitine
An O-acyl-L-carnitine in which the acyl group specified is hydroxyvaleroyl in which the position of the hydroxy group is unspecified.
(1s,2s,4ar,8as)-1-isothiocyanato-4a-methyl-8-methylidene-2-(prop-1-en-2-yl)-octahydronaphthalene
(1s,10s,13s,14r,15s)-14-hydroxy-15-methyl-6-azatetracyclo[8.6.0.0¹,⁶.0²,¹³]hexadec-2-en-11-one
(1r,2r,3r,5r,7r,7ar)-5-[(3s)-3-hydroxybutyl]-3-(hydroxymethyl)-hexahydro-1h-pyrrolizine-1,2,7-triol
4-[(2s)-1-isopropyl-4-methyl-5,6-dihydro-2h-pyridin-2-yl]-5-methylbenzene-1,3-diol
(10e)-n-(2-methylbutyl)dodeca-2,4,8,10-tetraenimidic acid
(1s,4s,10s,13s,15r)-4-hydroxy-15-methyl-6-azatetracyclo[8.6.0.0¹,⁶.0²,¹³]hexadec-2-en-11-one
n-{[(1r,9s)-6-oxo-7,11-diazatricyclo[7.3.1.0²,⁷]trideca-2,4-dien-11-yl]methyl}ethanimidic acid
(6r,6as,8r,10s,10ar)-6,6a,8,10-tetramethyl-6h,7h,8h,9h,10h,10ah-isochromeno[4,3-c]pyridin-1-ol
n-(2-methylpropyl)-12-oxododeca-2,4,8,10-tetraenimidic acid
(2r,3r,6r)-6-[(1e,3e,5e,7e)-deca-1,3,5,7-tetraen-1-yl]-1,2-dimethylpiperidin-3-ol
8-deoxy-13-dehydroserratinine
{"Ingredient_id": "HBIN013703","Ingredient_name": "8-deoxy-13-dehydroserratinine","Alias": "NA","Ingredient_formula": "C16H23NO2","Ingredient_Smile": "CC1CC2CC(=O)C3CCN4C3C2(CCC4)C(=O)C1","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "38592","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}
